NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Tarsus Pharmaceuticals, Inc. TARS
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$451.4M
▲ 146.7% vs FY2024
EPS · FY25
$-1.59
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-23.4%
Net margin · FY25
-14.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 451.4M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 15 cents on every revenue dollar this year.
Per share
USD -1.59
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-23.4%
Return on equity, FY2025
ROE
Operating margin-15.7%
Net margin-14.7%
Return on assets-14.1%
Each USD of equity lost 23 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+159.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+109.4%
Change, 10 years—
The share count grew 109% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 562.2M
total assets, end of FY2025
Total assetsUSD 562.2M
EquityUSD 343.4M
CashUSD 183.6M
Gross debtUSD 72.4M
Net debtUSD -111.2M
Current ratio3.85×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.5
0.2
0.0
0.0
0.1
0.0
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
·
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.59
−3.07
−4.62
−2.52
−0.67
−4.32
−1.98
·
Dividend / sh $
0.00
0.00
0.00
0.00
0.00
0.00
0.00
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−23.4
−54.8
−69.7
−34.5
−8.3
−33.5
·
·
Shares out B
0.04
0.04
0.03
0.03
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed